Severe Phenotype in Patients with Large Deletions of NF1
暂无分享,去创建一个
S. Julia | E. Pasmant | A. Sabbagh | M. Vidaud | I. Laurendeau | D. Vidaud | B. Gilbert-Dussardier | P. Nitschké | Laurence Pacot | A. Briand-Suleau | Audrey Coustier | H. Dollfus | B. Parfait | B. Dauriat | S. Ferkal | M. Fradin | J. Mazereeuw-Hautier | M. Vantyghem | Y. Alembik | A. Taieb | G. Nicolas | J. Lespinasse | V. Layet | D. Geneviève | B. Leheup | F. Petit | S. Bourthoumieu | S. Sigaudy | Y. Capri | E. Mutez | C. Quélin | L. Ruaud | L. Damaj | A. Guerrot | M. Nizon | F. Audic | H. Nasser | P. Wolkenstein | O. Glazunova | F. Morice-Picard | G. Hickman | Théodora Maillard | C. Barbance | É. Pasmant | A. Jannic | R. Stoeva | S. Audebert‐Bellanger | Magali Drouard | M. Lackmy | A. Lemaire | Anne Dieux Coeslier | Members Of The Nf France Network | Lyse Ruaud
[1] L. Kluwe,et al. Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth , 2021, PLoS genetics.
[2] K. Ross,et al. suz12 inactivation in p53- and nf1-deficient zebrafish accelerates the onset of malignant peripheral nerve sheath tumors and expands the spectrum of tumor types , 2020, Disease Models & Mechanisms.
[3] C. Assaiante,et al. Are morphological and structural MRI characteristics related to specific cognitive impairments in neurofibromatosis type 1 (NF1) children? , 2020, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[4] C. Indolfi,et al. Functional and morphological cardiovascular alterations associated with neurofibromatosis 1 , 2020, Scientific Reports.
[5] P. Lapunzina,et al. Co‐occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2 , 2020, Molecular genetics & genomic medicine.
[6] A. Bayat,et al. Neurological manifestations of neurofibromatosis: a review , 2020, Neurological Sciences.
[7] S. Steinberg,et al. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. , 2020, Neuro-oncology.
[8] B. Korf,et al. An Update on Neurofibromatosis Type 1-Associated Gliomas , 2020, Cancers.
[9] Eun Key Kim,et al. Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types , 2019, Journal of Human Genetics.
[10] G. Finocchiaro,et al. Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype–Phenotype Correlations in a Large Independent Cohort , 2019, Cancers.
[11] Michael F. Wangler,et al. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in neurofibromatosis type 1 , 2019, Human mutation.
[12] D. Gutmann,et al. Brain tumors in neurofibromatosis type 1 , 2019, Neuro-oncology advances.
[13] M. Digilio,et al. Prevalence, Type, and Molecular Spectrum of NF1 Mutations in Patients with Neurofibromatosis Type 1 and Congenital Heart Disease , 2019, Genes.
[14] D. Gutmann,et al. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1 , 2019, Journal of neuroscience research.
[15] D. Baralle,et al. Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation , 2018, Journal of Medical Genetics.
[16] Michael F. Wangler,et al. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation , 2018, Genetics in Medicine.
[17] T. Hershey,et al. Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1 , 2018, Neurology. Clinical practice.
[18] B. Korf,et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study , 2018, Orphanet Journal of Rare Diseases.
[19] E. Zackai,et al. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848 , 2017, American journal of human genetics.
[20] M. Kinori,et al. Ophthalmic manifestations in neurofibromatosis type 1. , 2017, Survey of ophthalmology.
[21] A. Vélez van Meerbeke,et al. Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1 , 2017, Front. Pediatr..
[22] A. Cacchione,et al. Growth hormone excess in children with neurofibromatosis type‐1 and optic glioma , 2017, American journal of medical genetics. Part A.
[23] D. Bianchessi,et al. Identification of an atypical microdeletion generating the RNF135-SUZ12 chimeric gene and causing a position effect in an NF1 patient with overgrowth , 2017, Human Genetics.
[24] I. Laurendeau,et al. Confirmation of mutation landscape of NF1‐associated malignant peripheral nerve sheath tumors , 2017, Genes, chromosomes & cancer.
[25] Kimberly J. Johnson,et al. Neurofibromatosis type 1 , 2017, Nature Reviews Disease Primers.
[26] D. Cooper,et al. Emerging genotype–phenotype relationships in patients with large NF1 deletions , 2017, Human Genetics.
[27] S. Perreault,et al. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature. , 2016, Pediatric neurology.
[28] H. Kehrer-Sawatzki,et al. Growth in neurofibromatosis 1 microdeletion patients , 2016, Clinical genetics.
[29] Ying Liu,et al. High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype–Phenotype Correlation , 2015, Human mutation.
[30] M. Peschanski,et al. In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells , 2015, Proceedings of the National Academy of Sciences.
[31] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[32] C. Bizzarri,et al. Endocrine Implications of Neurofibromatosis 1 in Childhood , 2015, Hormone Research in Paediatrics.
[33] H. Blanché,et al. NF1 single and multi-exons copy number variations in neurofibromatosis type 1 , 2015, Journal of Human Genetics.
[34] R. Margraf,et al. Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1 , 2015, Journal of Medical Genetics.
[35] M. Digilio,et al. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas , 2014, European Journal of Human Genetics.
[36] Eric Legius,et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.
[37] E. Pasmant,et al. Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations? , 2014, European Journal of Human Genetics.
[38] M. Vihinen,et al. Novel association of neurofibromatosis type 1‐causing mutations in families with neurofibromatosis‐noonan syndrome , 2014, American journal of medical genetics. Part A.
[39] H. Blanché,et al. NF1 Molecular Characterization and Neurofibromatosis Type I Genotype–Phenotype Correlation: The French Experience , 2013, Human mutation.
[40] D. O. Onu,et al. Charcot-Marie-Tooth syndrome and neurofibromatosis type 1 with multiple neurofibromas of the entire spinal nerve roots , 2013, BMJ Case Reports.
[41] M. Goldacre,et al. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study , 2012, British Journal of Cancer.
[42] G. Stacy,et al. Musculoskeletal manifestations of neurofibromatosis type 1. , 2012, AJR. American journal of roentgenology.
[43] D. Cooper,et al. Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis , 2011, Human Genomics.
[44] J. Lefaucheur,et al. At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control Study , 2011, Orphanet journal of rare diseases.
[45] K. Shah. The diagnostic and clinical significance of café-au-lait macules. , 2010, Pediatric clinics of North America.
[46] D. Cooper,et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions , 2010, Journal of Medical Genetics.
[47] M. Sanson,et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype , 2010, Human mutation.
[48] T. Pietsch,et al. Natural history and management of low-grade glioma in NF-1 children , 2010, Journal of Neuro-Oncology.
[49] S. Ekvall,et al. Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1 , 2009, Clinical genetics.
[50] J. Soulier,et al. Technical Advance Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH , 2009 .
[51] E. Pasmant,et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. , 2009, Human molecular genetics.
[52] A. Guzel,et al. Neurofibromatosis type 1 associated with Charcot–Marie–Tooth type 1A , 2009, The Journal of dermatology.
[53] Michael A Babcock,et al. Neurofibromatosis Type 1 Revisited , 2009, Pediatrics.
[54] N. Thomas,et al. Germline and somatic NF1 gene mutations in plexiform neurofibromas , 2008, Human mutation.
[55] I. Bièche,et al. Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient , 2008, European Journal of Human Genetics.
[56] J. Zeller,et al. Association between benign and malignant peripheral nerve sheath tumors in NF1 , 2005, Neurology.
[57] J. Lambert,et al. Pigment cell-related manifestations in neurofibromatosis type 1: an overview. , 2005, Pigment cell research.
[58] R. Siebert,et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene , 2004, Human mutation.
[59] D. Cooper,et al. Evaluation of genotype-phenotype correlations in neurofibromatosis type 1 , 2003, Journal of medical genetics.
[60] J. Friedman,et al. Analysis of intrafamilial phenotypic variation in neurofibromatosis 1 (NF1) , 2002, Genetic epidemiology.
[61] C. Romano,et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. , 2000, American journal of medical genetics.
[62] G Mortier,et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.
[63] J. Friedman,et al. Growth charts for young children with neurofibromatosis 1 (NF1) , 2000, American journal of medical genetics.
[64] R. Tenconi,et al. Neurofibromatosis type 1 growth charts. , 1999, American journal of medical genetics.
[65] M Super,et al. A clinical study of type 1 neurofibromatosis in north west England , 1999, Journal of medical genetics.
[66] J. Carey,et al. Neurofibromatosis-Noonan syndrome. , 1998, American journal of medical genetics.
[67] X. Estivill,et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. , 1997, American journal of human genetics.
[68] A. Deimling,et al. Neurofibromatosis Type 1: Pathology, Clinical Features and Molecular Genetics , 1995, Brain pathology.
[69] D. Easton,et al. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. , 1993, American journal of human genetics.
[70] Margaret Robertson,et al. The neurofibromatosis type 1 gene encodes a protein related to GAP , 1990, Cell.
[71] S. Huson,et al. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. , 1989, Journal of medical genetics.
[72] S. Huson,et al. Ophthalmic manifestations of neurofibromatosis. , 1987, The British journal of ophthalmology.
[73] D. Gutmann,et al. Optic Pathway Gliomas in Neurofibromatosis Type 1 , 2018, Journal of child neurology.
[74] E. Haan,et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. , 2007, American journal of human genetics.
[75] J. Dietemann,et al. [Imaging features of neurofibromatosis type 1]. , 2005, Journal of neuroradiology. Journal de neuroradiologie.
[76] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[77] J. Lupski,et al. Stable inheritance of the CMT1A DNA duplication in two patients with CMT1 and NF1. , 1993, American journal of medical genetics.
[78] D. Dunn,et al. Neurofibromatosis, Charcot-Marie-Tooth disease, or both? , 1989, Neurofibromatosis.
[79] National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. , 1988, Neurofibromatosis.